Loading...

Harpoon Therapeutics

DB:5HT
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5HT
DB
$273M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
  • Harpoon Therapeutics has significant price volatility in the past 3 months.
5HT Share Price and Events
7 Day Returns
-10%
DB:5HT
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-
DB:5HT
-5.6%
DE Biotechs
-4.5%
DE Market
5HT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Harpoon Therapeutics (5HT) -10% 13.1% - - - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • No trading data on 5HT.
  • No trading data on 5HT.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Harpoon Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Harpoon Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Harpoon Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Harpoon Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €9.843.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Harpoon Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Harpoon Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5HT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-25.65
NasdaqGS:HARP Share Price ** NasdaqGS (2019-04-25) in USD $11.22
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Harpoon Therapeutics.

DB:5HT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:HARP Share Price ÷ EPS (both in USD)

= 11.22 ÷ -25.65

-0.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Harpoon Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Harpoon Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Harpoon Therapeutics's expected growth come at a high price?
Raw Data
DB:5HT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-22.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Harpoon Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Harpoon Therapeutics's assets?
Raw Data
DB:5HT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-38.66
NasdaqGS:HARP Share Price * NasdaqGS (2019-04-25) in USD $11.22
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:5HT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:HARP Share Price ÷ Book Value per Share (both in USD)

= 11.22 ÷ -38.66

-0.29x

* Primary Listing of Harpoon Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Harpoon Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Examine Harpoon Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Harpoon Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Harpoon Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Harpoon Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Harpoon Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-22.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Harpoon Therapeutics expected to grow at an attractive rate?
  • Unable to compare Harpoon Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Harpoon Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Harpoon Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:5HT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:5HT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -22.1%
DB:5HT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 41.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5HT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5HT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 38 -83 -85 2
2022-12-31 0 -65 -112 2
2021-12-31 1 -50 -89 4
2020-12-31 5 -39 -61 3
2019-12-31 5 -36 -45 4
DB:5HT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 5 -27 -27
2018-09-30 4 -8 -23
2017-12-31 1 2 -17
2016-12-31 -11 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Harpoon Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Harpoon Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5HT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Harpoon Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5HT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.46 -2.46 -2.46 1.00
2022-12-31 -3.25 -3.25 -3.25 1.00
2021-12-31 -3.31 -3.28 -3.33 2.00
2020-12-31 -2.46 -1.81 -2.93 3.00
2019-12-31 -1.87 -1.72 -2.01 3.00
DB:5HT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -25.65
2018-09-30 -22.51
2017-12-31 -18.81
2016-12-31 -21.61

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Harpoon Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Harpoon Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Harpoon Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Harpoon Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Harpoon Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Harpoon Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Harpoon Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Harpoon Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Harpoon Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Harpoon Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5HT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.75 -27.37 6.11
2018-09-30 4.40 -22.58 4.80
2017-12-31 0.71 -16.83 3.61
2016-12-31 -11.41 3.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Harpoon Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Harpoon Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Harpoon Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Harpoon Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Harpoon Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Harpoon Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Harpoon Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Harpoon Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Harpoon Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Harpoon Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Harpoon Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Harpoon Therapeutics Company Filings, last reported 3 months ago.

DB:5HT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 76.10 0.00 89.49
2018-09-30 15.85 0.00 27.86
2017-12-31 12.90 0.00 29.42
2016-12-31 4.48 2.31 0.99
  • Harpoon Therapeutics has no debt.
  • Harpoon Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Harpoon Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Harpoon Therapeutics has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 47.4% each year.
X
Financial health checks
We assess Harpoon Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Harpoon Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Harpoon Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Harpoon Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Harpoon Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Harpoon Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Harpoon Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5HT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5HT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Harpoon Therapeutics has not reported any payouts.
  • Unable to verify if Harpoon Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Harpoon Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Harpoon Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Harpoon Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Harpoon Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Harpoon Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Harpoon Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Harpoon Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jerry McMahon
COMPENSATION $880,276
AGE 63
TENURE AS CEO 2.3 years
CEO Bio

Dr. Gerald McMahon, also known as Jerry, Ph.D., has been the President, Chief Executive Officer at Harpoon Therapeutics, Inc., since January 2017 and has been its Director since December 2016. Dr. McMahon serves as a Strategic Advisor to large and small companies related to their R&D pipeline including support of their financing, portfolio strategy and business development activities. From May 2012 until Celldex's acquisition of Kolltan in November 2016, Dr. McMahon served as President and Chief Executive Officer and a member of the board of directors of Kolltan, a private biopharmaceutical company. Prior to joining Kolltan, Dr. McMahon served as Senior Vice President of Oncology at MedImmune LLC, a wholly owned subsidiary of the healthcare company AstraZeneca AB, or AstraZeneca, from October 2010 to May 2012. Prior to joining Kolltan, he held various roles leading private and public biotechnology companies, where he was instrumental in the discovery and development of oncology products that led to approvals worldwide and generated substantial value for patients and shareholders. From 2006 to 2008, Dr. McMahon served as the Chairman and Chief Executive Officer of the pharmaceutical company NeoRx Corp. He is leading the global R&D effort in oncology biologics for AstraZeneca. He joined MedImmune in 2010, where he manages the functions to discover and develop the R&D pipeline including in licensing, Partnering, external alliances and other investments. He served as the Chief Executive Officer at Poniard Pharmaceuticals, Inc. from May 11, 2004 to February 5, 2010 and also served as its President from June 15, 2005 to May 2007. He served as Principal Operating Officer of Poniard Pharmaceuticals, Inc. He has spent more than 20 years as a Business Executive in the healthcare and biotech industries. Previously, Dr. McMahon served as a business executive in the healthcare and biotechnology industries at companies such as Pfizer Inc., Pharmacia Corporation, and Sandoz, Inc. He was employed 10 years at SUGEN, where he was instrumental to build the business leading to the successful discovery, development and regulatory approvals of novel oncology drugs including Sutent(R) and Palladia(R). He served as the President of SUGEN, Inc. since 2003. He served as Vice President of Drug Discovery at Sugen, Inc. since January 1998. He served as a Venture Partner at Bay City Capital. He served as the Chief Executive Officer and in various boards of Directors roles for public and private healthcare companies. He served as the Chairman of at Poniard Pharmaceuticals, Inc. from May 2004 to January 2, 2011. He was a Director of Celldex Therapeutics, Inc. since December 14, 2016 until December 5, 2018. He served as a Director of Mateon Therapeutics, Inc. (Alternate Name: OXiGENE, Inc.) from September 2011 to November 23, 2016. He served as a Director of Trellis Bioscience, Inc. He served as a Director of Poniard Pharmaceuticals, Inc. since June 2004. He was Director of Sandoz. He served as a Staff Scientist and Principal Investigator at the Massachusetts Institute of Technology and Tufts University School of Medicine early in his career. He served academic appointments at the Tufts University School of Medicine, Department of Hematology & Oncology at the New England Medical Center and the Massachusetts Institute of Technology, where he has authored over 87 publications and holds 67 U.S. patents. Dr. McMahon holds a B.S. in Biology and earned a Ph.D. in 1980 in Biochemistry from Rensselaer Polytechnic Institute. He held Post-Graduate appointments at Tufts Medical School in Boston and the Massachusetts Institute of Technology in Cambridge, Massachusetts.

CEO Compensation
  • Jerry's compensation has been consistent with company performance over the past year.
  • Jerry's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Harpoon Therapeutics management team in years:

1
Average Tenure
53
Average Age
  • The average tenure for the Harpoon Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Luke Evnin

TITLE
Chairman of the Board
COMPENSATION
$29K
AGE
55

Jerry McMahon

TITLE
President
COMPENSATION
$880K
AGE
63
TENURE
2.3 yrs

Holger Wesche

TITLE
Chief Scientific Officer
COMPENSATION
$557K
AGE
50
TENURE
0.5 yrs

Natalie Sacks

TITLE
Chief Medical Offer
COMPENSATION
$705K
AGE
53
TENURE
0.5 yrs

Georgia Erbez

TITLE
Chief Financial Officer
AGE
51
TENURE
0.5 yrs

Rachael Lester

TITLE
Vice President of Corporate Development
TENURE
1.5 yrs

Susan Jones

TITLE
Senior Vice President of Product Development
TENURE
1.5 yrs

Chris Whitmore

TITLE
Vice President of Finance
Board of Directors Tenure

Average tenure and age of the Harpoon Therapeutics board of directors in years:

1.9
Average Tenure
54
Average Age
  • The average tenure for the Harpoon Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jerry McMahon

TITLE
President
COMPENSATION
$880K
AGE
63
TENURE
2.3 yrs

Mark Chin

TITLE
Director
COMPENSATION
$29K
AGE
36
TENURE
1.9 yrs

Luke Evnin

TITLE
Chairman of the Board
COMPENSATION
$29K
AGE
55
TENURE
4.3 yrs

Ron Hunt

TITLE
Director
COMPENSATION
$29K
AGE
53
TENURE
1.9 yrs

Julie Eastland

TITLE
Director
COMPENSATION
$52K
AGE
53
TENURE
0.5 yrs

Scott Myers

TITLE
Director
COMPENSATION
$45K
AGE
52
TENURE
0.7 yrs

John Drachman

TITLE
Director
COMPENSATION
$66K
AGE
56
TENURE
0.6 yrs

Patrick Baeuerle

TITLE
Director
COMPENSATION
$150K
AGE
60
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Feb 19 Buy MPM Capital Company 12. Feb 19 12. Feb 19 226,660 €12.37 €2,804,192
14. Feb 19 Buy Arix Bioscience plc Company 12. Feb 19 12. Feb 19 428,571 €12.37 €5,302,195
14. Feb 19 Buy New Leaf Venture Partners, L.L.C. Company 12. Feb 19 12. Feb 19 428,571 €12.37 €5,302,195
X
Management checks
We assess Harpoon Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Harpoon Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Details
Name: Harpoon Therapeutics, Inc.
5HT
Exchange: DB
Founded: 2015
$245,182,798
24,339,830
Website: http://www.harpoontx.com
Address: Harpoon Therapeutics, Inc.
4000 Shoreline Court,
Suite 250,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS HARP Common Stock Nasdaq Global Select US USD 08. Feb 2019
DB 5HT Common Stock Deutsche Boerse AG DE EUR 08. Feb 2019
Number of employees
Current staff
Staff numbers
45
Harpoon Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 23:30
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/22
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.